Does aGS16F be a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma?
AGS16F is a promising new therapeutic option for patients with RCC and is currently being evaluated in a phase I clinical trial.
In line with previous data suggesting an abnormally broad attentional spotlight and enhanced perceptual function in individuals with ASD, the results of this study suggest enhanced awareness of the visual scene in ASD. The results of this study could reflect superior top-down control of visual search in autism, enhanced perceptual function, or inefficient filtering of visual information in ASD.